<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650947</url>
  </required_header>
  <id_info>
    <org_study_id>09-58-16</org_study_id>
    <nct_id>NCT02650947</nct_id>
  </id_info>
  <brief_title>Sucralose Effects on Glucose Metabolism and Gut Microbiota</brief_title>
  <official_title>Effects of Sucralose Consumption on Glucose Metabolism, Incretin and Gut Microbiota in Healthy Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Endocrine Society of Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

        1. Long-term consumption of sucralose may effect glucose metabolism, incretin hormone
           secretion and gut microbiota in healthy adults.

        2. Long-term consumption of sucralose may alter food behaviour in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Artificial sweeteners such as sucralose, are among the most widely used food additives
      worldwide. Artificial sweetener consumption is considered safe and beneficial owing to their
      low caloric content. However, many emerging evidences showed artificial sweeteners may induce
      glucose intolerance. The objectives of this study were to determine the effect of sucralose
      on glycemic response, insulin secretion, insulin sensitivity, incretin response, gut
      microbiota and food behavior in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of sucralose on insulin secretion</measure>
    <time_frame>2 hours</time_frame>
    <description>We will measure plasma insulin concentrations before and at 0, 2, 3, 4, 5, 6, 8, 10 minutes after administered intravenously 50%glucose 0.3 g/kg within 1 minute. All these data collected were used to calculate acute insulin response to glucose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide-1 secretion</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>4 weeks</time_frame>
    <description>stool exam, polymerase chain reaction for 16s RNA gene using next generation sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food record</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of sucralose on insulin sensitivity</measure>
    <time_frame>2 hours</time_frame>
    <description>We will measure plasma insulin concentrations during an oral glucose tolerance test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sucralose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group ate capsule filled with sucralose 200 mg for 4 weeks (week 1-4) and measured oral glucose tolerance test (OGTT), acute insulin response (AIR), and gut microbe examination at week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects ate empty capsule (placebo) for 4 weeks (week 1-4) and measured OGTT, AIR, and gut microbe examination at week 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucralose</intervention_name>
    <description>Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks</description>
    <arm_group_label>Sucralose</arm_group_label>
    <other_name>Trichlorosucrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Consumption of empty capsule everyday for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers without underlying disease

          -  Normal oral glucose tolerance test

          -  Agree to participate by written informed consent

        Exclusion Criteria:

          -  Shift workers

          -  History of diabetes mellitus or prediabetes (impaired fasting glucose and/or glucose
             tolerance test)

          -  Malabsorption problem

          -  Regular consumption of nonnutritive sweeteners

          -  Liver impairment (aspartate aminotransferase (AST) and/or alanine aminotransferase
             (ALT) &gt; 3-folds upper normal limit)

          -  Renal impairment (serum creatinine &gt;1.5 mg/dL)

          -  Use of medications affecting glucose level such as glucocorticoid, estrogen, androgen

          -  Pregnant and lactating woman

          -  Smoking within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chutintorn Sriphrapradang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramathibodi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ramathibodi Hospital</investigator_affiliation>
    <investigator_full_name>Chutintorn Sriphrapradang</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Sucralose</keyword>
  <keyword>Insulin Secretion</keyword>
  <keyword>Insulin Sensitivity</keyword>
  <keyword>Incretin</keyword>
  <keyword>Gut Microbiota</keyword>
  <keyword>Food and Eating Behaviour</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 21, 2017</submitted>
    <returned>October 10, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

